The FDA announcing a unified platform for tracking adverse events is a welcome technical improvement. Consolidating fragmented databases and making reports easier to access is long overdue. Transparency and better data tools are always a step in the right direction. That said, modernizing the reporting interface doesn’t automatically resolve the deeper concerns many people have about the system itself. Passive reporting databases have always had limitations—underreporting, inconsistent data quality, and the inability to establish causation without deeper investigation. More importantly, the real criticism directed at the FDA over the years hasn’t been about the lack of dashboards or databases. It’s been about trust, transparency in decision-making, regulatory independence, and whether safety signals are investigated thoroughly and communicated openly. A new platform may make the data easier to see, which is good. But rebuilding confidence in public health institutions requires more than improved software—it requires consistent accountability, rigorous oversight, and a willingness to confront uncomfortable findings when they arise. Technology can improve visibility. Trust still has to be earned.